Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2018, Article ID 5067239, 3 pages
https://doi.org/10.1155/2018/5067239
Case Report

A Case of Spondyloarthritis in Patient Affected by Unicentric Castleman’s Disease Effectively Managed with Surgery Resection and Tocilizumab Treatment

1Unità Operativa di Reumatologia, Spedali Civili di Brescia, Brescia, Italy
2Unità Operativa di Medicina Interna, Azienda Ospedaliera di Desenzano del Garda, Desenzano del Garda, Italy
3Unità Operativa di Ematologia, Spedali Civili di Brescia, Brescia, Italy
4Università degli Studi di Brescia, Brescia, Italy

Correspondence should be addressed to M. Filippini; ti.aigolotamueraicserb@inippilif

Received 3 August 2017; Revised 4 December 2017; Accepted 12 December 2017; Published 23 January 2018

Academic Editor: Jamal Mikdashi

Copyright © 2018 M. Filippini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Soumerai, A. R. Sohani, and J. S. Abramson, “Diagnosis and management of Castleman disease,” Cancer Control, vol. 21, no. 4, pp. 266–278, 2014. View at Publisher · View at Google Scholar
  2. G. De Marco, S. De Vita, M. Fabris, C. A. Scott, and G. Ferraccioli, “Systemic connective tissue disease complicated by Castleman’s disease: report of a case and review of the literature,” Haematologica, vol. 89, no. 4, pp. 7–10, 2004. View at Google Scholar
  3. T. Gracia-Cazana, C. Delgado-Beltran, M. A. Concellon, and M. A. Fuertes, “Mixed connective tissue disease in a patient with Castleman disease and Hodgkin lymphoma: excellent clinical response to rituximab,” Actas Dermo-Sifiliográficas, vol. 106, no. 10, pp. 843–846, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Ishikawa, T. Kato, M. Aragaki et al., “A case of Castleman’s disease with myasthenia gravis,” Annals of Thoracic and Cardiovascular Surgery, vol. 20, pp. 585–588, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Wang, S. W. Chen, S. L. Cai, and B. Y. Jin, “A case report of retroperitoneal pararenal Castleman’s disease associated with myasthenia gravis,” World Journal of Surgical Oncology, vol. 12, no. 1, p. 331, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Jakubikova, J. Pitha, J. Latta, E. Ehler, and J. Schutzner, “Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome,” Muscle Nerve, vol. 47, no. 3, pp. 447–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Shariatpanahi, S. Pourfarzam, and M. Gheini, “Association of macrophage activating syndrome with Castleman’s syndrome in systemic lupus erythematosus,” Irananian Journal of Pathology, vol. 11, no. 3, pp. 265–271, 2016. View at Google Scholar
  8. M. Rudwaleit, D. van der Heijde, R. Landewe et al., “The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 25–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. W. Muskardin, B. A. Peterson, and J. A. Molitor, “Castleman disease and associated autoimmune disease,” Current Opinion in Rheumatology, vol. 24, no. 1, pp. 76–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. F. van Rhee, K. Stone, S. Szmania, B. Barlogie, and Z. Singh, “Castleman disease in the 21st century: an update on diagnosis, assessment and therapy,” Clinical Advances in Hematology & Oncology, vol. 8, no. 7, pp. 486–498, 2010. View at Google Scholar
  11. S. J. Brandt, D. M. Bodine, C. E. Dunbar, and A. W. Nienhuis, “Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice,” Journal of Clinical Investigation, vol. 86, no. 2, p. 592, 1990. View at Publisher · View at Google Scholar
  12. K. L. Chan, S. Lade, H. M. Prince, and S. J. Harrison, “Update and new approaches in the treatment of Castleman disease,” Journal of Blood Medicine, vol. 7, pp. 145–158, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Sieper, B. Porter Brown, L. Thompson, O. Harari, and M. Dougados, “Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials,” Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 95–100, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Merashli, G. De Marco, M. Podgorski, D. McGonagle, and H. Marzo-Ortega, “Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis,” Annals of the Rheumatic Diseases, vol. 75, no. 7, pp. 1418–1420, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Casper, “The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care,” British Journal of Haematology, vol. 129, no. 1, pp. 3–17, 2005. View at Publisher · View at Google Scholar · View at Scopus